Therefore, a future study should be conducted on patients with BMI greater >30 to further analyze the significance of this interaction between PNPLA3 gene and BMI in the contest of prediabetes and progression of NAFLD to significant fibrosis. The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatotic liver disease.